NeuCeptin (trastuzumab biosimilar) / NeuClone, Serum Institute of India - LARVOL DELTA

[VIRTUAL] NeuClone (BIO 2020) - "NeuClone's pipeline consists of 20 biosimilars, six of which have been disclosed referencing Stelara (ustekinumab), Herceptin (trastuzumab), Perjeta (pertuzumab), Synagis (palivizumab), Prolia (denosumab) and Humira (adalimumab)...Additional biosimilars referencing Perjeta, Prolia, Synagis and more are undergoing manufacturing scale-up ahead of initiating clinical trials. NeuClone is exploring potential partnerships for biosimilar mAbs through clinical development and commercialisation into North America, Europe and other selected developed world and emerging markets."

Oncology

NeuClone announces positive results from phase I study of Herceptin (trastuzumab) biosimilar candidate (Businesswire) - P1, N=104; ACTRN12618001657213; Sponsor: NeuClone; "NeuClone Pharmaceuticals Ltd....announced that NeuCeptin, a biosimilar candidate of Herceptin® (trastuzumab), has successfully met all primary and secondary endpoints in a Phase I clinical trial. This includes all pre-specified criteria demonstrating clinical pharmacokinetic (PK) similarity of NeuCeptin, compared to US- and EU-sourced Herceptin®. Additionally, the safety and tolerability profiles were equivalent between all three treatment arms."

P1 data